Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 26-29    DOI: 10.31083/j.ejgo.2021.01.2230
Review Previous articles | Next articles
Primary debulking surgery of advanced epithelial ovarian cancer in developing countries: challenges and expectations
Sigit Purbadi1, *(), Kade Yudi Saspriyana2, 3
1Gynaecology Oncology Division, Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National Referral Hospital, 10430 Jakarta, Indonesia
2Fellowship Gyanecology Oncology Trainee, Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Indonesia, 10430 Jakarta, Indonesia
3Department of Obstetric and Gynecology, Faculty of Medicine, Udayana University, Sanglah General Hospital, 80113 Bali, Indonesia
Download:  PDF(166KB)  ( 60 ) Full text   ( 19 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Ovarian cancer often presents itself in advanced stages and can be accompanied by various comorbidities. Treatment options are primary debulking surgery (PDS) followed by adjuvant chemotherapy, or alternatively, neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The option taken is based on several considerations. If the patient can be treated with PDS, the absence of macroscopic residual disease becomes an independent prognostic factor. However, achieving this outcome is a challenge for the gynaecologic oncologist since advanced stage ovarian cancer generally metastasizes into the peritoneum and the upper abdominal organs. Optimal outcomes are that surgery will be safe for the patient, no macroscopic residual disease is achieved, minimal postoperative complications are encountered, and a good survival rate is obtained. Developed countries, especially Europe, have well-recognized standards of care which are followed by developing countries; however, challenges with insurance coverage and inter-departmental cooperation are recognized hurdles in developing countries. Competency improvement along with good inter-departmental communication and collaboration are keys to optimal outcomes for PDS.
Key words:  Ovarian cancer      Primary debulking surgery      Residual disease      Interdepartmental approach      Competency     
Submitted:  25 August 2020      Revised:  07 October 2020      Accepted:  20 October 2020      Published:  15 February 2021     
*Corresponding Author(s):  Sigit Purbadi     E-mail:  spurbadi@gmail.com

Cite this article: 

Sigit Purbadi, Kade Yudi Saspriyana. Primary debulking surgery of advanced epithelial ovarian cancer in developing countries: challenges and expectations. European Journal of Gynaecological Oncology, 2021, 42(1): 26-29.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2230     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/26

[1] Tadahiro Shoji, Kotoka Kikuchi, Hayato Kogita, Nanako Jonai, Hidetoshi Tomabechi, Akiko Kudoh, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba. New treatment strategy for ovarian cancer with a BRCA gene mutation[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 1-9.
[2] Ece Gumusoglu, Tuba Gunel, Mohammad Kazem Hosseini, Nogayhan Seymen, Taylan Senol, Uğur Sezerman, Samet Topuz, Kılıç Aydınlı. The importance of dysregulated miRNAs on ovarian cysts and epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 66-72.
[3] Min Jong Song, Suk Il Jang, Hyon Jee Yoon, Eun Young Ki, Joon Mo Lee, Soo Young Hur. Classical HLA class I antigen downregulation and abnormal HLA-G expression in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 129-138.
[4] Joseph J. Noh, Kyue-Hee Choi, Hyun-Soo Kim, Jeong-Won Lee. Port site implantation of clear cell carcinoma after laparoscopic ovarian cystectomy[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 174-178.
[5] Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.
[6] Irina Esteves-Krasteva, José Ángel Minguez, José María Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Gabriel Zozaya-Larequi, Juan Luis Alcázar, Matías Jurado. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 906-912.
[7] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[8] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[9] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta, Miwa Yasaka, Hiroko Machida, Masae Ikeda, Masako Shida, Takeshi Hirasawa, Mikio Mikami. Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 960-968.
[10] Fatih Kose, Songül Alemdaroğlu, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ozan Cem Güler, Seda Yüksel Şimşek, Gürcan Erbay, Cem Önal, Hüsnü Çelik. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 989-995.
[11] R van de Vrie, E van Werkhoven, M J Rutten, J D Asseler, H S van Meurs, D E Werter, M R Buist, A.H. Zwinderman, C A R Lok, P.M.M. Bossuyt, G G Kenter, P Tajik. Validation of a treatment-selection rule for patients with advanced stage ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1023-1030.
[12] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[13] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[14] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[15] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
No Suggested Reading articles found!